Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
SB 735 would reauthorize and expand a federal sickle cell disease demonstration program under the Public Health Service Act. It updates the program’s stated purpose so that it covers not only the treatment of sickle cell disease, but also the prevention and treatment of complications associated with the disease. The bill also broadens the types of federal support that may be used, allowing the Secretary of Health and Human Services to make grants, enter into contracts, or use cooperative agreements with eligible entities.
The legislation increases the authorized funding level for the program from $4,455,000 per year for fiscal years 2019 through 2023 to $8,205,000 per year for fiscal years 2025 through 2029. In addition to the statutory changes, the bill includes a sense of Congress stating that further research should be undertaken to better understand the causes of heritable blood disorders and to find cures for them, including sickle cell disease. The bill is framed as a reauthorization and expansion measure rather than a new program.
Overall, the bill appears to be aimed at strengthening federal research, surveillance, prevention, and treatment efforts for sickle cell disease and related inherited blood disorders. Its practical effect would be to extend and enlarge an existing federal program, increase available funding, and support a wider range of public health partnerships and interventions. The bill would primarily affect the Department of Health and Human Services and entities that receive federal support for sickle cell-related work, such as research institutions, health providers, and community-based organizations.
There is no recorded committee transcript or vote history provided, so there is no documented opposition or support beyond the bill’s introduction and referral. The sponsorship by Senators Scott and Booker suggests bipartisan or cross-party interest in sickle cell policy, and the bill’s language is focused on public health and research expansion. Because no debate is included, no specific points of contention are evident in the available materials.
The bill would amend section 1106(b) of the Public Health Service Act to expand the scope of the sickle cell demonstration program, authorize grants, contracts, and cooperative agreements, and raise the annual authorization of appropriations to $8,205,000 for fiscal years 2025 through 2029. It would affect federal public health administration and funding for sickle cell disease and other heritable blood disorder initiatives, especially for research, surveillance, prevention, treatment, and complication management.
The available context suggests broadly positive and supportive sentiment. The bill is introduced as a reauthorization and expansion of an existing public health program, with no recorded votes or committee debate indicating opposition. The bipartisan sponsorship and the emphasis on research, treatment, and cures point to a generally constructive and noncontroversial posture in the materials provided.
No specific contention is documented in the provided record because there are no committee transcripts or votes. Potential areas that could draw scrutiny, based on the text alone, would be the increased authorization level, the expanded federal role through grants and cooperative agreements, and the breadth of the program’s focus on complications and related heritable blood disorders. However, no member or stakeholder objections are identified in the available materials.